VRNA - Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs Analysts Predict Big Moves | Benzinga
In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion (£1.6 billion) range over the upcoming six months, aiming to fortify its pipeline.
Miels emphasized a specific interest in assets within the respiratory and autoimmune disease sectors, expressing a preference for single-asset or dual-asset entities in potential acquisitions.
H.C. Wainwright notes that the inclination suggests a strategic opportunity for GSK to consider Verona Pharma Plc (NASDAQ: VRNA) as a potential acquisition target, with a market capitalization of approximately $1.6 billion, which presents an attractive prospect.
Its ...